Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine
Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics
Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00https://www.sandoz.com/rss/feeds/news/media-releases.xmlhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pnghttps://www.sandoz.com/rss/feeds/news/media-releases.xml2018-04-18 02:00:002018-04-18 02:00:00Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine
Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics
Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00https://www.sandoz.com/rss/feeds/news/media-releases.xmlhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pnghttps://www.sandoz.com/rss/feeds/news/media-releases.xml2018-04-18 02:00:002018-04-18 02:00:00Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
